MacroGenics, Inc. (MGNX)
- Previous Close
14.6700 - Open
4.5000 - Bid 3.2600 x 100
- Ask 3.3400 x 200
- Day's Range
3.1500 - 4.8800 - 52 Week Range
3.1400 - 21.8800 - Volume
34,941,647 - Avg. Volume
2,024,725 - Market Cap (intraday)
207.075M - Beta (5Y Monthly) 2.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1500 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.80
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
www.macrogenics.comRecent News: MGNX
Performance Overview: MGNX
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MGNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MGNX
Valuation Measures
Market Cap
207.08M
Enterprise Value
11.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.58
Price/Book (mrq)
1.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-53.60%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
43.36M
Net Income Avi to Common (ttm)
-23.24M
Diluted EPS (ttm)
-0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
229.8M
Total Debt/Equity (mrq)
22.26%
Levered Free Cash Flow (ttm)
--
Research Analysis: MGNX
Company Insights: MGNX
MGNX does not have Company Insights